Evolus (NASDAQ:EOLS) Releases Earnings Results, Misses Expectations By $0.09 EPS

Evolus (NASDAQ:EOLS) released its quarterly earnings data on Tuesday. The company reported $0.00 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09), reports. The firm had revenue of $90.30 million for the quarter, compared to the consensus estimate of $89.58 million.

Here are the key takeaways from Evolus’ conference call:

• Company highlights portfolio momentum — Jeuveau reached ~14% U.S. toxin share and Evolysse has >3,000 purchasing accounts with Evolysse Sculpt expected to file/receive FDA approval in Q4 and a large sampling program planned for Q2 2026.
• Solid 2025 performance and explicit 2026 targets — full‑year 2025 revenue was $297.2M (+12%)$90.3M (+14%)$327M–$337M with an expectation of full‑year profitability (low‑to‑mid single‑digit adjusted EBITDA) and 13%–15% adjusted EBITDA by 2028.
• Improved cost structure and liquidity — management rebased expenses in mid‑2025, expects non‑GAAP OpEx of $210M–$216M in 2026 (0%–3% growth), ended Q4 with $53.8M cash and access to a revolving facility plus additional debt tranches, and says it is not planning an equity raise.
• Ongoing market and policy headwinds — U.S. injectable procedural volumes declined in 2025, the filler market remains pressured, and Evolus products imported from France are currently subject to a 15% tariff (possible further tariff risk and uncertain recovery of prior tariffs), while new competitor toxin launches in 2026 could create near‑term sampling pressure.

Evolus Trading Up 26.2%

Shares of EOLS traded up $1.08 during midday trading on Wednesday, reaching $5.21. The stock had a trading volume of 5,787,031 shares, compared to its average volume of 1,225,346. The company has a market capitalization of $337.71 million, a price-to-earnings ratio of -5.66 and a beta of 1.02. The company’s 50-day moving average is $5.11 and its 200 day moving average is $6.24. Evolus has a 12-month low of $4.09 and a 12-month high of $14.60.

Trending Headlines about Evolus

Here are the key news stories impacting Evolus this week:

• Positive Sentiment: BTIG Research reaffirmed a “buy” rating and set a $13.00 price target (~122% upside from recent levels), which can attract bullish flows and coverage-driven buying. BTIG Reaffirmation
• Positive Sentiment: Evolus raised FY2026 revenue guidance to $327M–$337M, above the Street (~$316.3M), signaling stronger top-line momentum and supporting upside to estimates. 2026 Revenue Guidance
• Positive Sentiment: Company press release highlights near-$300M 2025 revenue, sixth consecutive year of double-digit growth, and a stated expectation of sustainable profitability beginning in 2026 — a strategic narrative that supports a re-rating if execution continues. BusinessWire Results
• Positive Sentiment: Quarterly revenue of $90.3M came in slightly above analyst estimates (~$89.6M), providing a tangible beat on the top line despite mixed commentary on margins and EPS. Quarterly Results Deck
• Neutral Sentiment: Earnings call transcripts and highlights are available for detail on growth drivers (international expansion, product portfolio) and management’s cadence for profitability; useful for modeling but not an immediate catalyst on their own. Earnings Call Transcript
• Neutral Sentiment: Zacks reported EPS of $0.06 that matched its consensus — this suggests some analysts see the quarter as in-line even as revenue and guidance pushed the stock higher. Zacks EPS Report
• Neutral Sentiment: Reported short-interest data shows anomalies (zeros/NaN), indicating the published short-interest figures are unreliable right now and shouldn’t be treated as a clear supply signal. Short Interest Data
• Negative Sentiment: There are conflicting EPS reports across outlets (some note a miss vs. consensus and others report an in-line beat), creating near-term uncertainty about profitability and margins that could temper multiple expansion until numbers are reconciled. Mixed EPS Reporting

Analyst Ratings Changes

EOLS has been the subject of several analyst reports. HC Wainwright cut their price target on shares of Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Mizuho set a $15.00 price objective on Evolus in a research note on Wednesday, February 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd. Stifel Nicolaus lowered their price target on Evolus from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, January 13th. Finally, Wall Street Zen upgraded Evolus from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Evolus has a consensus rating of “Moderate Buy” and an average price target of $17.50.

Insider Buying and Selling at Evolus

In related news, insider David Moatazedi sold 10,539 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $7.15, for a total value of $75,353.85. Following the completion of the sale, the insider owned 354,388 shares in the company, valued at $2,533,874.20. The trade was a 2.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Evolus

A number of hedge funds have recently made changes to their positions in EOLS. Meeder Asset Management Inc. bought a new position in shares of Evolus during the fourth quarter valued at about $34,000. Wexford Capital LP purchased a new stake in Evolus in the 3rd quarter worth approximately $37,000. Tower Research Capital LLC TRC grew its position in shares of Evolus by 340.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock worth $68,000 after buying an additional 5,691 shares during the last quarter. Aquatic Capital Management LLC bought a new stake in shares of Evolus in the 3rd quarter worth approximately $48,000. Finally, State of Wyoming purchased a new position in shares of Evolus during the fourth quarter valued at approximately $63,000. 90.69% of the stock is currently owned by institutional investors.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.